Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-26T01:34:09.506Z Has data issue: false hasContentIssue false
  • English
  • Français

Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression

Published online by Cambridge University Press:  16 April 2020

Shigeru Morishita  and
Seizaburo Arita
Shigeru Morishita*
Affiliation:
Depression Prevent Medical Center, Kyoto Jujo Hospital, 32 Kisshoinhattandacho, Minaki-Ku, Kyoto601-8325, Japan
Seizaburo Arita
Affiliation:
Department of Mathematics, Kansai Medical School, Hirakata, Osaka, Japan
*
*Corresponding author. Email addresses:[email protected]
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

FluvoxamineParoxetineMilnacipranInhibitionAgitation
Type
Case report
Information
European Psychiatry , Volume 19 , Issue 7 , November 2004 , pp. 450 - 451
Copyright
Copyright © European Psychiatric Association 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiat 1960;23:56–62.CrossRefGoogle ScholarPubMed
Hamilton, M. Frequency of symptoms in melancholia (depressive illness). Br J Psychiatry 1989;154:201–6.CrossRefGoogle ScholarPubMed
Kielholz, P, Poeldinger, W. Pharmacotherapy of endogenous depression. Compr Psychiatry 1968;9:179–86.Google ScholarPubMed
Kielholz, P. The classification of depressions and the activity profile of the antidepressants. Prog Neuropsychopharmacol 1979;3:59–63.CrossRefGoogle ScholarPubMed
Kielholz, P. Treatment for therapy-resistant depression. Psychopathology 1986;19(Suppl 2):194–200.CrossRefGoogle ScholarPubMed
Nelson, JCN. Safety and tolerability of the new antidepressants. J Clin Psychiatry 1977;58(Suppl 6):26–31.Google Scholar
Puech, A, Montgomery, SA, Prost, JF, Solles, A, Briley, M. Milnacipran, A new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychop-harmaco 1997;12:99–108.CrossRefGoogle ScholarPubMed
Schildkraut, JJ. The catecholamine hypothesis of affective disorders: a review of the supporting evidence. Am J Psychiatry 1965;122:509–22.CrossRefGoogle ScholarPubMed
Stahl, SM, Mendels, J, Schwartz, GE. Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials. J Clin Psychopharmacol 2002;22:388–92.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.